On Monday, the U.S. Food and Drug Administration (FDA) approved the first injection drug for HIV pre-exposure prevention. 
The FDA <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention">approved</a> use of the drug Apretude “(cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV.”
The drug is first carried out as two injections given with one month of separation, and every two months afterwards. People can either start by getting the Apretude injection or take the oral drug cabotegravir (Vocabria) for four weeks to see how they do with the medication.
The FDA explained the trials that were carried out: 
<blockquote>
The safety and efficacy of Apretude to reduce the risk of acquiring HIV were evaluated in two randomized, double-blind trials that compared Apretude to Truvada, a once daily oral medication for HIV PrEP. Trial 1 included HIV-uninfected men and transgender women who have sex with men and have high-risk behavior for HIV infection. Trial 2 included uninfected cisgender women at risk of acquiring HIV.
…
In Trial 1, 4,566 cisgender men and transgender women who have sex with men received either Apretude or Truvada. The trial measured the rate of HIV infections among trial participants taking daily cabotegravir followed by Apretude injections every two months compared to daily oral Truvada. The trial showed participants who took Apretude had 69% less risk of getting infected with HIV when compared to participants who took Truvada. 
In Trial 2, 3,224 cisgender women received either Apretude or Truvada. The trial measured the rate of HIV infections in participants who took oral cabotegravir and injections of Apretude compared to those who took Truvada orally. The trial showed participants who took Apretude had 90% less risk of getting infected with HIV when compared to participants who took Truvada.
Side effects occurring more frequently in participants who received Apretude compared to participants who received Truvada in either trial include injection site reactions, headache, pyrexia (fever), fatigue, back pain, myalgia and rash.
</blockquote>
It added, &#8220;Apretude includes a boxed warning to not use the drug unless a negative HIV test is confirmed. &#8230; Individuals who become infected with HIV while receiving Apretude for PrEP must transition to a complete HIV treatment regimen. The drug labeling also includes warnings and precautions regarding hypersensitivity reactions, hepatotoxicity (liver damage) and depressive disorders.&#8221;
The FDA noted that the drug administer every two months instead of a daily pill medication is an “Important Tool in [the] Effort to End the HIV Epidemic.”
NBC News <a href="https://www.nbcnews.com/nbc-out/out-health-and-wellness/fda-approves-first-injectable-hiv-prevention-drug-rcna9426">reported</a> that “[w]hile gains have been made in PrEP use over the past several years, only 25 percent of the 1.2 million people for whom PrEP is recommended were prescribed the treatment last year, according to the Centers for Disease Control and Prevention. The CDC estimates that as of 2019, there were approximately 285,000 people using PrEP, the vast majority of them gay and bisexual men.”
“Today’s approval adds an important tool in the effort to end the HIV epidemic by providing the first option to prevent HIV that does not involve taking a daily pill,” said Debra Birnkrant, M.D., who is the director of the Division of Antivirals in the FDA’s Center for Drug Evaluation and Research. “This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option.”
The Hill <a href="https://thehill.com/policy/healthcare/586735-fda-approves-first-hiv-prevention-injection">reported</a>, “Approximately 1.7 million new HIV cases are identified every year. Those who get infected with HIV while taking Apretude are instructed to transition to an HIV treatment regimen.”
In an <a href="https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2021/december/viiv-healthcare-announces-fda-approval-of-apretude/">announcement</a>, ViiV Healthcare said it &#8220;will begin shipping Apretude to wholesalers and specialty distributors in the U.S. in early 2022. ViiV Healthcare has initiated submissions to other regulatory authorities. Apretude has not been approved or licensed anywhere outside of the U.S. for use in HIV prevention.&#8221;
Per the company&#8217;s website, &#8220;ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline [&#8230;] and Pfizer [&#8230;] dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV.&#8221;
Americans have become more familiarized with the FDA over the course of the last several years as the process for getting treatments and vaccines approved has been brought to light through the coronavirus pandemic. 
This week, a Tuesday report from Bloomberg stated that the U.S. Food and Drug Administration could <a href="https://www.dailywire.com/news/report-fda-could-approve-pfizer-merck-covid-pills-in-next-few-days">authorize</a> use of COVID-19 pills by Pfizer and Merck as early as this week. 
Some have started to consider the FDA and CDC as political tools, perhaps contributing to the apparent rise of distrust in American institutions. 
Last week, the FDA <a href="https://www.dailywire.com/news/fda-to-make-abortion-pills-available-through-the-mail">removed</a> restrictions from the distribution of the abortion pill, allowing it to be given out in different settings rather than the method by which it has been issued in the past. The new development will now allow the medication abortion to be sent through the mail and even potentially purchased or acquired online.

<script async src="https://www.instagram.com/embed.js"></script>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<script async src="https://www.tiktok.com/embed.js"></script><div data-widget-host="revcontent" data-pub-id="165152" data-widget-id="290588"></div><script src="https://delivery.revcontent.com/165152/290588/widget.js"></script>

FDA Approves HIV Prevention Drug As Shot

CONTINUE READING

The Unanswered Question At The Center Of The SCOTUS Idaho Abortion Decision

How The Pro-Life Movement Can Positively Influence Laws Surrounding Fertility Treatments

Why Supporting Pregnant Incarcerated Women Is a Pro-Life Stand

Why Children Need Parents To Put The Phone Down And Look Them In The Eye

Postpartum Depression And The Devaluation Of Motherhood 

Why Gen Z Is Turning To Dating Apps To Find Friends, Fight Loneliness

News and Commentary

A video goes viral showing a baby being refused his mother by two gay "dads". This is just the tip of the iceberg, which is why we will have an important discussion today about surrogacy. 

Hour 1

The Matt Walsh Show

Ep. 1765 - This Video Is One Of The Worst Things I've Seen In A Long Time 

The Strait of Hormuz officially opens for business (kind of), the Pope makes “shocking” comments on immigration, and President Trump promises UFO disclosure at TPUSA. 


The Michael Knowles Show

Ep. 1956 -  Pope Leo's "SHOCKING" Immigration Comments EXPLAINED

A false miscreed has corrupted our leadership class.


The Andrew Klavan Show

Ep. 1275 - Dumb, Dumber and Progressive

President Trump announces a 10-day ceasefire between Lebanon and Israel, a murder-suicide involving former Democratic Lieutenant Governor Justin Fairfax shakes Virginia, and France and Britain hold a conference to secure the Strait of Hormuz – after the Iranian conflict ends. Get the facts first with Morning Wire.

- - -

Ep. 2738

- - -

Wake up with new Morning Wire merch: https://bit.ly/4lIubt3

- - -

Today's Sponsors:

Alliance Defending Freedom - Visit https://JoinADF.com/WIRE or text 'WIRE' to 83848 to learn more.

Pocket Hose - Text MORNING to 64000 to get a FREE pocket pivot and their 10-pattern sprayer with the purchase of ANY size Copper Head hose. Message and data rates may apply.

Morning Wire

U.S. Expands Hormuz Blockade & VA Fairfax Deaths Investigated | 4.17.26

U.S. Expands Hormuz Blockade & VA Fairfax Deaths Investigated | 4.17.26 [Member Exclusive]

A ceasefire goes into effect between Israel and Lebanon, a tragic murder-suicide rocks Virginia, and Dairy Queen deploys AI in the drive-thru. Get the facts first with Evening Wire.
- - -
Ep. 2737
- - -
Wake up with new Morning Wire merch: https://bit.ly/4lIubt3 
- - -
Today’s Sponsor:

Alliance Defending Freedom - Visit https://JoinADF.com/WIRE or text “WIRE” to 83848 to learn more.


Menu

— News and Commentary —

FDA Approves HIV Prevention Drug As Shot